NXC736
NXC736 is in Phase 2 for alopecia areata, developed by NEXTGEN Bioscience.
An oral candidate from a Korean sponsor, recruiting a Phase 2 in moderate to severe alopecia areata since 2024, described in the company's patent as a sphingosine-1-phosphate receptor antagonist.
- Developed by
- NEXTGEN Bioscience
- Current phase
- Phase 2
- Mechanism
- Immunomodulator
- Indications
- Alopecia areata
- Also known as
- NXC-736, NXC 736
- Last public activity
- April 2026
- Copy last reviewed
- September 2026
- Record confidence
- Low
Tests whether it works, at what dose, in a few hundred people.
Retunes the immune system more broadly than a single pathway.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
The registry entry describes a randomised, placebo-controlled, double-blind study of an oral drug in 73 adults with moderate or severe disease at two Seoul sites, with completion expected in January 2027, and excludes patients who have taken an oral JAK inhibitor. NEXTGEN Bioscience has issued no release about it. The company's US patent names NXC736 as a functional antagonist of the S1PR1 and S1PR4 receptors and reports oral dosing in the standard mouse model of alopecia areata; that is the only public description of the molecule. Etrasimod, an oral S1P modulator also in this register, has been through a Phase 2 in the same disease.
Development history
- Phase 2
First Phase 2 trial on record: NCT06104839 — Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
NEXTGEN Bioscience · n=73 · September 2024
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
Related programmes
Other programmes in the register with the same mechanism: Immunomodulator.
Cite this page
Hair Pipeline, "NXC736 — development record", hairpipeline.com/pipeline/nxc736